Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Busy address KBO
74 other companies have their registered office at the same address; threshold 10.
-
Not on Peppol Peppol
Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.
Financials
Financial year 2024
Bio-Tech-Business from Elsene, company number BE0637774802, closed financial year 2024 with a result of € 2,125 after tax. For that financial year Bio-Tech-Business recorded a gross margin of € 4,521 and equity of € 45,756. Compared with financial year 2023, the result moved from € -8,535 to € 2,125. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on October 6, 2025.
€ 45,756
▲ 5% vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 2,125
▲ still € 8,535 loss in 2023
Profit after tax over the fiscal year.
€ 519
▲ 17% vs 2023
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2024. Retained profit grew to € 39,556.
People and assets in 2024
≈ 1
No payroll staff. One director, so that person most likely runs the business.
€ 6
▼ 61% vs 2023
Book value of vehicles, furniture and equipment.
Debts at end 2024
None
No bank loans on the last day of the fiscal year.
€ 12,863
▲ 3% vs 2023
Supplier invoices still open on the last day of the fiscal year.
€ 12,550
▼ 2% vs 2023
Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2021 | 2022 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|---|
| Gross margin | € -41,398 | € -8,556 | € -5,395 | € 4,521 | ▲ € 9,916 |
| Profit after taxes | € -42,281 | € -23,038 | € -8,535 | € 2,125 | ▲ € 10,659 |
| Equity | € 75,129 | € 52,091 | € 43,556 | € 45,756 | ▲ 5% |
| Total debts | € 2,532 | € 17,206 | € 25,308 | € 25,413 | |
| Cash | € 21,313 | € 315 | € 442 | € 519 | ▲ 17% |
| Retained profit | € 68,929 | € 45,891 | € 37,356 | € 39,556 | ▲ 6% |
| Balance sheet total | € 77,661 | € 69,297 | € 68,863 | € 71,169 | ▲ 3% |
Key figures of Bio-Tech-Business, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 July 2026.
What happened to Bio-Tech-Business?
What happened at Bio-Tech-Business in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: profit of € 2,125. filed late Source: NBB ↗
- New establishment in Elsene. KBO
- Start of the company according to the CBE. KBO
- Xavier QUILLIET became a director. NBB
In short
From € 42,281 loss in 2021 to € 2,125 profit in 2024.
Paid € 12,772 in corporate taxes since 2021.
Best year ever: 2024, with € 2,125 profit.
A new publication or filing at Bio-Tech-Business? We notify you, reason included.
Follow Bio-Tech-BusinessDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind Bio-Tech-Business is Xavier QUILLIET.
Directors
According to the 2024 annual accounts
Xavier QUILLIET
Director
since 2015
Establishments
Establishment units
Physical locations of this company
Gachardstraat 88
1050 Elsene
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 74 companies are registered at this address.
All companies at this address →Casteau Homes
Prevent, Instituut voor Preventie en Welzijn op het Werk
Association des Chefs de Service de Securité et d'Hygiène de Belgique - Vereniging van Diensthoofden voor veiligheid en Hygiëne van België
Centre de Prévention du Suicide
€ 103,939 revenue · 2025
EFMD
€ 6.3 million revenue · 2025
+69 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0637.774.802
- VAT number
- BE 0637.774.802
- Registered office
- Gachardstraat 88, 1050 Elsene
- Names & denominations
- Bio-Tech-Business
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 15 September 2015
- Peppol
- Not registered
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering